Benefit-Risk Assessment of Chinese Medicine Injections for Primary Liver Cancer Based on Multi-criteria Decision Analysis

Rong-Rong Zhang; Ming-Yi Shao; Yu Fu; Rui-Xia Zhao; Jing-Wen Wnag; Yu-Xuan Fang

doi:10.1007/s11655-023-3704-2

Benefit-Risk Assessment of Chinese Medicine Injections for Primary Liver Cancer Based on Multi-criteria Decision Analysis

Chin J Integr Med. 2023 Sep 12. doi: 10.1007/s11655-023-3704-2. Online ahead of print.

Authors

Rong-Rong Zhang¹, Ming-Yi Shao², Yu Fu³, Rui-Xia Zhao³, Jing-Wen Wnag⁴, Yu-Xuan Fang¹

Affiliations

¹ The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou, 450046, China.
² Personal Department, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China. shmy1016@163.com.
³ Scientific Research Department, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
⁴ Digestive Department, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.

PMID: 37697203
DOI: 10.1007/s11655-023-3704-2

Abstract

Objective: To evaluate the benefit-risk of 3 commonly used Chinese medicine injections, Aidi Injection (ADI), Cinobufagin Injection (CINI) and Compound Kushen Injection (CKI), in the treatment of primary liver cancer (PLC), so as to provide a reference for clinical decision-making.

Methods: Randomized controlled trials (RCTs) of ADI, CINI and CKI in the treatment of PLC published in the databases of China National Knowledge Infrastructure, Wanfang, China Science and Technology Journal Database, SinoMed, PubMed, Cochrane Library, and Web of Science were retrieved from January 2020 to October 2022. The data of benefit and risk indicators were combined to obtain the effect value. The multi-criteria decision analysis (MCDA) model was applied to build the decision tree. The benefit value, risk value and benefit risk value of the 3 injections in PLC treatment were calculated. Monte Carlo simulation was carried out to calculate the 95% confidence interval and probability of differences among the 3 injections, so as to optimize the evaluation results.

Results: A total of 71 RCTs were included. The benefit values of ADI, CINI and CKI combined with transcatheter arterial chemoembolization (TACE) were 42, 38 and 36, respectively. The risk values were 42, 25 and 37, respectively. The benefit risk values were 42, 31 and 37, respectively. The benefit risk differences of ADI vs. CINI, ADI vs. CKI, and CKI vs. CINI were 11 (-0.86, 17.75), 5 (-5.01, 11.09), and 6 (-1.87, 12.63), respectively. The probability that ADI superior to CINI, ADI superior to CKI, and CKI superior to CINI was 96.26%, 77.27%, and 92.62%, respectively.

Conclusion: Based on the results of MCDA model, CINI combined with TACE has the greatest risk in the treatment of the PLC. Considering the efficacy and safety, the possible priority of the 3 Chinese medicine injections combined with TACE in the treatment of PLC is ADI, CKI and CINI.

Keywords: Chinese medicine injections; benefit-risk assessment; multi-criteria decision analysis; primary liver cancer.